novo nordisk cuts glp-1 drug prices for cash-paying customers. Nordisk, Eli Lilly cut costs under Medicare wegovy #ozempic #glp1 #obesity #biotech

Rapid weight loss disrupts this balance

Consequently, other strategies for oral administration have been tested and developed, including (but not limited to) coadministration with enzyme inhibitors, structural modifications [cyclization, PEGylation, fatty acid conjugates of polypeptides (lipidization), fusing therapeutic proteins to cobalamin (vitamin B 12 )], and the use of delivery carriers or absorption enhancers

Lean et al., 2014) significantly improve glycemic control and cause a significant body weight loss in T2DM patients

As GLP1-RAs are more likely to be prescribed in patients who has weight to lose, perhaps, we might be getting some confounding effect from obesity

writing-review and editing, Meiling Hao